Your SlideShare is downloading. ×
Inovio Pharmaceuticals 2012 Investor Presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Inovio Pharmaceuticals 2012 Investor Presentation

607
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
607
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. J. Joseph Kim, Ph.D.President & CEO Page 1
  • 2. Forward Looking StatementOur commentary and responses to your questions may contain forward-lookingstatements, including comments concerning clinical trials and productdevelopment programs, evaluation of potential opportunities, the level ofcorporate expenditures, the assessment of Inovio’s technology by potentialcorporate partners, capital market conditions, timing of events, cashconsumption and other subjects. Information concerning factors that couldcause actual results to differ materially from those set forth in our AnnualReport on Form 10-K for the year ended December 31, 2011, our Form 10-Qfor the quarter ended June 30, 2012, and other regulatory filings from time totime. Page 2
  • 3. Inovio: Revolutionizing Vaccines• Inovio’s synthetic vaccine technology designed to: • Treat some of today’s most challenging diseases • Universally protect against changing infectious disease strains • Break the body’s tolerance of cancerous cells• Targeting unmet needs with multi-billion dollar potential: cancers, universal flu, HIV, hepatitis B/C virus• Multiple ongoing clinical trials: phase II and phase I• Industry-leading potency & safety • Best-in-class immune responses for cervical dysplasia & HIV• Dominant global IP position (424 patents issued/pending)• Validation: • $35M+ in non-dilutive grant funding over last few years • Advancing discussions for vaccine product development partnerships and further grant funding Page 3
  • 4. Conventional Vaccines Increased life expectancy• Saved millions from sickness/death• Added decades to life expectancy• Deliver a virus or part of a virus to expose a unique antigen (foreign protein)• Generate antibodies that prevent targeted diseases from infecting cells• Low hanging fruit picked – old Five decade-old technology is great . . . technology has reached its limitations but does not solve tomorrow’s challenges• Safety concerns: can cause the disease or other bad side effects• Rely on technology that is often more than 50 years old; some vaccines are still grown in chicken eggs Page 4
  • 5. Synthetic DNA Vaccine Platform Revolutionizing vaccines through:• Strong safety profile• SynCon® “designer vaccines” give the body the DNA instructions to produce only the targeted antigen - nothing more• Generate powerful T-cells to kill infected cells or tumors (therapeutic vaccines)• Manufacturing advantages: rapid, scalable, thermal-stable Page 5
  • 6. SynCon® Universal Vaccine DesignImmune responses more cross-reactive (universal)than those induced by single-strain vaccines Page 6
  • 7. Superior Vaccine Delivery Using Electroporation > 10-100x enhancement in immune responses Page 7
  • 8. Best-in-Class Immune Responses in Humans Immune Responses T Cell Responses Antibody ResponsesInovio Clinical Clinical Results Competition Inovio Clinical Clinical Competition Study Study ResultsHPV-001 Best in class T Adenovirus vectors FLU-001/002 Broad StockpiledCervical cell responses MVA vectors H5N1 protective inactivatedCancer/ (magnitude and DNA vaccines Pandemic Flu antibody vaccinesDysplasia durability) Peptides/proteins titers against 6 different H5N1 strainsHVTN-080 Best in class T Adenovirus vectors FLU-101 Broad TrivalentPreventive HIV cell responses MVA vectors Universal Flu – protective inactivatedVaccine (magnitude and DNA vaccines H1N1 antibody virus vaccines durability) Peptides/proteins titers against (TIV) Combinations 9 different Live-attenuated H1N1 strains vaccines Page 8
  • 9. Inovio’s Strategy• Advance/validate SynCon® + electroporation platform • Best in-class immunogenicity established in human studies• Develop proprietary products through proof-of-concept human data (phase I or phase II)• Maximize resources/opportunities; spread cost/risk • Non-dilutive third party funding • Direct: R&D grants – $35M received since 2008 • Indirect: clinical trials sponsored by outside agencies – Seven ongoing studies • Partner/out-license product for preclinical/clinical development and marketing Page 9
  • 10. Inovio Product Pipeline: Cancers Pre- Indication Product (Antigen) Phase I Phase II Partner/Funding Milestone clinical Cervical Dysplasia VGX-3100 (E6/E7 2H 2013 Therapeutic Type 16/18 HPV) Phase II study data (Wilms’ tumor University of 4Q 2012 LeukemiaCancers gene 1) Southampton Interim Phase II data INO-5150 1H 2013 Prostate (PSA + PSMA) Initiate Phase I Breast/Lung/ V934 Merck Prostate (hTERT) Internally Funded Page 10 Partner Funded/Supported
  • 11. Inovio Product Pipeline: Infectious Diseases Pre- Indication Product (Antigen) Phase I Phase II Partner/Funding Milestone clinical 4Q 2012 (NS3/4A) + SOC ChronTech Phase II interim data Hepatitis C Virus Therapy PA CARE Grant/ 2H 2013 INO-8000 (NS3/4A, NS4B, NS5A) VGX Inter Initiate Phase I Phase I final data HIV Vaccine PENNVAX-B submitted for Trials Network publication HIV Preventive 1H 2013 AdditionalInfectious Diseases PENNVAX-G USMHRP/NIAID Phase I data 1Q 2013 PENNVAX-GP NIH/NIAID Initiate Phase I University of 4Q 2012 HIV Therapeutic PENNVAX-B Final Phase I data Pennsylvania Pandemic Influenza Manuscript in VGX-3400X preparation -Avian (H5N1) Universal Influenza – NIH Transformative 1Q 2013 INO-3510 Healthy Adults Research Award Add’l Phase I data U. of Manitoba/ Universal Influenza – 1Q 2013 FVH1 Canadian Institute of (H1N1) in Elderlies Interim Phase I data Health Research Internally Funded Page 11 Partner Funded/Supported
  • 12. VGX-3100: Cervical Dysplasia/Cancer Therapy• Cervical cancer: ~500,000 cases, 250,000 deaths yearly• Cervical dysplasias (CIN) preceding cancer (U.S. annually) • CIN 1: 1.4 M ; CIN 2/3: 300,000• VGX-3100 phase I • 18 patients, 3 dose levels • Vaccine safe and well-tolerated • Most robust T-cells generated by T cell a DNA vaccine in humans responses by other • Stronger responses than other Low Mid High All vaccines Dose Level vaccines, including viral vectors • Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4 • Durable responses: 12 of 13 responders (92%) displayed persistent, strong T-cell responses at month 9 Page 12
  • 13. VGX-3100: Phase II Study• Randomized, blinded, placebo controlled• > 25 sites in multiple countries• 148 patients with CIN 2/3• Three vaccinations over 3 months, 6 months monitoring• Primary endpoint: CIN 2/3 lesion clearance at month 9• Initiated in 2011; enrollment ongoing• Efficacy data expected 2H 2013 Page 13
  • 14. Leukemia Vaccine: Phase II• Chronic myeloid leukemia (CML) 300,000+ new cases,• Acute myeloid leukemia (AML) 222,000 deaths yearly• Vaccine coded for Wilms’ tumor gene 1 (WT1) • Overexpressed in majority of acute leukemias• Open label phase II clinical trial • Active: 37 CML patients, 37 AML patients • Control group: 100-110 AML/CML patients, non-vaccinated • Primary endpoints • CML: molecular response to disease marker (BCR-ABL) • AML: time to disease progression• Initiated in 2011; enrollment ongoing; interim data expected 4Q 2012 Page 14
  • 15. ChronVac-C® Therapeutic Vaccine• Hepatitis C virus (HCV) • 3.5 million chronically infected in US; >170 million worldwide • Causes liver disease/cancer• Positive phase I study (HCV genotype 1): ChronVac-C + standard of care (SOC: interferon & ribavirin) • Safe & well-tolerated • Positive T-cell immune responses • Sustained viral response (SVR): 5 of 6 patients (83%)• Open label, randomized phase II study (32 patients) • Vaccinated (20): 2 vaccinations; Control (12): SOC only • Primary endpoints • Rapid viral response (4 weeks) • Partial early viral response (pEVR) (12 weeks) • Initiated in 2011; enrollment ongoing • Interim data expected 4Q 2012 Page 15
  • 16. PENNVAX-B: Phase I Studies• Preventive study, randomized, placebo-controlled: run by HVTN• Three vaccinations over 3 months; 48 vaccinated subjects, 3 arms: • 1 mg PENNVAX-B (n=10) • 1 mg PENNVAX-B + DNA IL-12 delivered via EP (n=30) • Placebo (n=8) • T-cell immune responses superior to all other previously-tested HIV vaccines • Submitted for publication T-cell Responses by intracellular cytokine staining (ICS) assay Positive Reponses Placebo Group Vaccine + DNA IL-12 + EP Total CD4 + CD8 0% (0/8) 88.9% (24/27)____________________________________________________________________________________________________________________________________• Therapeutic study, open label, 12 vaccinated subjects, run by UPenn• Significant antigen-specific CD8+ T-cell responses: • against at least 1 of 3 antigens (gag, pol, or env) in 75% of subjects Page 16
  • 17. SynCon® Universal Influenza Vaccines• H5N1 phase I data: • Strong T-cell/antibody responses • => 1:20 HAI titers – 71% positive responders to at least 1 H5N1 virus • Protection against all six unmatched H5N1 strains tested• H1N1 phase I data: • Significant # of responders exceeding 1:40 HAI titers against different strains • Protection against all nine unmatched H1N1 strains testedPotential to shift flu vaccinationfrom “one bug, one drug” approach topre-emptive, universal prevention acrossstrains, subtypes and years Page 17
  • 18. ManagementJ. Joseph Kim, Ph.D., President & Peter Kies, CFOCEO• Decades of biotechnology/pharma • Ex-Ernst & Young management • Experience with growth companies• Ex-Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&DNiranjan Y. Sardesai, Ph.D., COO Mark L. Bagarazzi, M.D., CMO• Extensive biotech management • Clinical research experience incl. and product development Merck experience • Led clinical/regulatory for shingles• Led development of diagnostics and rotavirus vaccines; DNA vaccine for mesothelioma, bladder expert cancer, and ovarian cancer for Fujirebio DiagnosticsManaged development and approval of several vaccines Page 18
  • 19. Board of DirectorsAvtar Dhillon, M.D., Chairman, BOD Morton Collins, Ph.D.• Former President & CEO, Inovio • General Partner, Battelle Ventures Biomedical and Innovations Valley PartnersSimon X. Benito J. Joseph Kim, Ph.D.• Former Senior Vice President, Merck • President & CEO, Inovio Vaccine DivisionAngel Cabrera, Ph.D. Adel Mahmoud, Ph.D.• President, George Mason University • Professor, Princeton University• Former President, Thunderbird School • Former President, Merck Vaccines of Global Management • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq® Page 19
  • 20. Scientific Advisory BoardDavid B. Weiner, Ph.D., Chairman, SAB• “Father of DNA vaccines”• Dept. of Pathology & Laboratory Medicine, U of PAThomas S. Edgington, M.D. Philip Greenberg, M.D.• Founded multiple biotech companies; • Expert in T-cell immunology extensively published • Head, Immunology Program, Fred• Emeritus Professor, Scripps Research Hutchinson Cancer Research Center InstituteAnthony W. Ford-Hutchinson, Ph.D. Stanley A. Plotkin, M.D.• Former SVP, Vaccines R&D, Merck • Developed rubella and rabies vaccines• Oversaw development: Singulair®, • Oversaw Sanofi flu vaccine Januvia®, Gardasil®, Zostavax®, • Emeritus Professor, Wistar Institute & Proquad® and Rotateq® U of Penn Page 20
  • 21. Financial Information Cash & short term investments1 $19.5 M Debt1 0M Burn rate ~$4.5 M/Q Cash runway 3Q 2013 Listing NYSE MKT: INO Issued & outstanding shares1 134.9 M Recent price2 $0.63 Market cap2 $85 M1 June 30, 2012 2 September 18, 2012 Page 21
  • 22. Investment Summary• Paradigm shifting synthetic vaccine platform displaying best-in- class immunogenicity and other characteristics significantly improving upon conventional and new competitive vaccine technologies• Strong management team with vast vaccine discovery & development expertise• Extensive third-party grant funding• Important validating clinical milestones over next quarters• Advancing discussions with large pharmaceutical companies with the goal of securing new partnerships to advance development and commercialization of SynCon® vaccines Page 22
  • 23. revolutionizing vaccines Investor Contact: Bernie Hertel Senior Director, Corporate Communications 858-410-3101 ● bhertel@inovio.comNYSE MKT: INO www.inovio.com

×